Analysts expect Mesoblast Ltd to report revenue of 181.67 M for 2027, against a range of 173.82 M to 189.52 M. The most recent reported year, 2026, came in at 120.25 M, a 0.6% miss against the 120.93 M consensus.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 10.21 M | 7.50 M | 5.90 M | 17.20 M | 120.25 M | - | - | ||
| High Estimate | 14.59 M | 8.87 M | 7.71 M | 18.96 M | 125.74 M | 189.52 M | 349.02 M | ||
| Low Estimate | 12.02 M | 7.38 M | 6.41 M | 17.72 M | 116.12 M | 173.82 M | 300.62 M | ||
| Consensus Estimate | 13.30 M | 8.12 M | 7.06 M | 18.34 M | 120.93 M | 181.67 M | 324.82 M |
Analysts expect Mesoblast Ltd to report earnings per share of -0.22 for 2027, against a range of -0.23 to -0.21. The most recent reported year, 2026, came in at -0.44, a 6.4% beat against the -0.47 consensus.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.33 | -1.05 | -0.89 | -0.85 | -0.44 | - | - | ||
| High Estimate | -0.96 | -1.06 | -0.51 | -0.53 | -0.45 | -0.21 | 0.12 | ||
| Low Estimate | -1.08 | -1.24 | -0.57 | -0.59 | -0.49 | -0.23 | 0.10 | ||
| Consensus Estimate | -1.02 | -1.15 | -0.54 | -0.56 | -0.47 | -0.22 | 0.11 |